Zogenix's long-acting hydrocodone meets chronic pain endpoint, ready for 2012 filing
18 August 2011
Nancy Faigen
Please Login to read the full article.
18 August 2011
Nancy Faigen
nancy.faigen@informausa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Alkermes' PhII ALKS-5461: new mechanism, opiate receptor modulation, for refractory depression
- Zogenix plans offering of 12M shares, as it moves forward on chronic pain product
- Zogenix adds $60 million equity to take lead to NDA and fund operations until 2013
- New malignancy concerns raised for Pfizer's JAK inhibitor ahead of AdCom
ANALYSIS
Other Informa Analysis
EVENTS
Today
Continental Zara Hotel, Budapest, Hungary
Today
Radisson Blu Royal Hotel, Dublin
Today
Hotel Sofitel Hamburg Alter Wall
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
